Literature DB >> 2352449

Gastric emptying and the pharmacokinetics of the cephalosporin antibiotic, cefpodoxime proxetil.

G S Hughes1, D L Heald, R Patel, C R Spillers, D H Batts, A R Euler.   

Abstract

The effects of gastric motility on the pharmacokinetics of cefpodoxime proxetil, an oral, broad spectrum, third-generation cephalosporin antibiotic were evaluated in 12 healthy subjects. In this open-label, crossover trial, each subject took a 200 mg dose (two 100 mg film-coated tablets) in each study period. There was an initial fasting period followed by a control period and then either a propantheline or metoclopramide period. Gastric motility was measured using [99mTc]-labeled sulfur colloid in oatmeal in the control, propantheline and metoclopramide periods. Treatment with propantheline or metoclopramide was given 30 min before dosing with the antibiotic and the radioisotope. Serial images with a gamma counter were made every 15 min for 2 h. Gastric emptying time was faster than control with metoclopramide, but generally slower with propantheline than control. The mean peak plasma concentration, mean area under plasma concentration time curve and mean half-life of cefpodoxime proxetil were similar in all groups as compared to control. The mean time to peak plasma concentration was delayed in the propantheline period and peak plasma concentrations were greater at all sampling times at six hours after dosing. This study utilized the gastric nuclear scan with modification of gastric motility by metoclopramide and propantheline and with simultaneous determination of the disposition of cefpodoxime proxetil to understand the absorption of the drug.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2352449

Source DB:  PubMed          Journal:  Methods Find Exp Clin Pharmacol        ISSN: 0379-0355


  5 in total

Review 1.  A review of the pharmacokinetics of cefpodoxime proxetil.

Authors:  M T Borin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 2.  Cefpodoxime proxetil in upper respiratory tract infections.

Authors:  E Bergogne-Berezin
Journal:  Drugs       Date:  1991       Impact factor: 9.546

3.  Pharmacokinetics and ex vivo susceptibility of cefpodoxime proxetil in patients receiving continuous ambulatory peritoneal dialysis.

Authors:  C A Johnson; A Ateshkadi; S W Zimmerman; G S Hughes; W A Craig; P M Carey; M T Borin
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

Review 4.  Cefpodoxime proxetil: a review of its use in the management of bacterial infections in paediatric patients.

Authors:  B Fulton; C M Perry
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 5.  Cefpodoxime proxetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential.

Authors:  J E Frampton; R N Brogden; H D Langtry; M M Buckley
Journal:  Drugs       Date:  1992-11       Impact factor: 9.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.